Goldman-Backed Biotech Attovia Seeks $212.5 Million in US IPO
THE SO WHAT
An early-stage immune-disease biotech targeting a $212.5M IPO shows public markets are still open to pre-revenue science stories with strong backers. If you’re building in deep tech, this is a reminder that capital is available for clear, focused theses—even before commercial validation.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureNothing Nefarious With 'Circle Financing': Dorrell
If Nvidia is working on more than $750B of AI-related deals and infra investors are normalizing structures like "circle financing," AI capex is becoming its own financial product. Operators should expect more creative, long-dated financing offers tied to compute usage—and read the fine print on control and lock-in.
Startups & VentureThis Cambridge startup is building a ‘foundation model’ for the chest to speed drug trials
Qureight’s $20m bet on a single “foundation model for the chest” is vertical AI in its purest form—one high-fidelity model, many downstream lung and heart trial applications. If you’re in clinical or imaging-heavy domains, assume the competitive bar is shifting from point models per disease to shared backbones tuned for your organ system or modality.
Startups & VentureVC is changing dramatically — what’s a founder to do?
With capital concentrating into a narrow AI barbell, default-yes rounds are gone for most categories. Founders should underwrite plans on revenue, venture debt, and angels first—then treat traditional VC as opportunistic fuel, not the core power source.
Startups & VentureAI agents don’t log in like people. That problem just sold for $1bn.
A $1 billion acquisition for Oasis Security around AI agent identity is a clear price tag on the “non-human account” problem. If you’re spinning up agents that touch real data, you now need an IAM strategy for bots—credentials, lifecycle, and audit—on par with what you use for employees.